Midazolam B. Braun (Midazolam Hydrochloride)

Midazolam Hydrochloride enhances the activity of the neurotransmitter GABA at the GABA‑A receptor. By increasing chloride ion flow into neurons, it hyperpolarizes the cell membrane, leading to reduced neuronal excitability and producing sedation, anxiolysis, muscle relaxation, and anticonvulsant effects.

The specific dose of Midazolam B. Braun is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and route of administration. Healthcare professionals adjust the dose to achieve the desired level of sedation or seizure control while monitoring safety.

Safety data for Midazolam during pregnancy and lactation are limited. It should only be used when the potential therapeutic benefit justifies any potential risk to the fetus or infant. Clinicians must evaluate each case individually and discuss risks with the patient.

To order Midazolam B. Braun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Midazolam has a rapid onset and short duration compared with agents such as diazepam or lorazepam, making it especially useful for procedural sedation and acute seizure control. Its water‑soluble formulation allows intravenous use, whereas some alternatives are only available in oral or intramuscular forms.

Midazolam B. Braun should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

The drug can be given intramuscularly, intravenously, or rectally, depending on the clinical indication. Intravenous administration provides the fastest onset, while intramuscular and rectal routes are used when IV access is not available or for specific procedural protocols.

The most serious risks include severe respiratory depression, which may require assisted ventilation, anaphylactic reactions, and paradoxical agitation or aggression. Prompt monitoring of respiratory function and readiness to intervene are essential during and after administration.

Midazolam B. Braun is contraindicated in patients with known hypersensitivity to midazolam or any component of the formulation, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in individuals who have had a severe adverse reaction to other benzodiazepines.